Jefferies Resumes Oxford BioMedica Coverage with Buy Rating and 41% Upside Potential

Key Facts

1Jefferies resumed coverage of Oxford BioMedica with a 'buy' rating and a price target of £8.27.

2The price target implies a 41% upside from the current share price of £5.88.

3Jefferies raised medium-term earnings estimates by 4% citing a manufacturing agreement with Bristol Myers Squibb.

Jefferies has resumed its coverage of Oxford BioMedica PLC with a "buy" rating, setting an ambitious price target of £8.27. This new target suggests a significant 41% upside potential compared to the current share price of £5.88. The investment bank also raised its medium-term earnings estimates for the company by 4%, citing a strategic manufacturing agreement with Bristol Myers Squibb (BMY). Analysts believe this partnership significantly de-risks the company's operations and strengthens its path toward sustainable profitability. The move reflects growing confidence in Oxford BioMedica's specialized role within the biotechnology and pharmaceutical sectors. This positive analyst sentiment is expected to drive increased investor interest in the London-listed equity.